Dupilumab for Atopic Dermatitis-From Clinical Trials to Molecular and Cellular Mechanisms.

Journal

Dermatitis : contact, atopic, occupational, drug

ISSN: 2162-5220

Titre abrégé: Dermatitis

Pays: United States

ID NLM: 101207335

Informations de publication

Date de publication:
08 Jun 2022

Historique:

entrez: 8 6 2022

pubmed: 9 6 2022

medline: 9 6 2022

Statut: aheadofprint

Résumé

Dupilumab is a monoclonal antibody that represents the first approved targeted biological therapy for adults, adolescents, and children older than 6 years with moderate-to-severe atopic dermatitis (AD). Dupilumab binds the shared chain of the interleukin-4 and interleukin-13 receptor blocking the downstream signaling of these cytokines. The clinical improvements induced by dupilumab were associated with remission of the dysregulated immune mechanisms linked with AD. Dupilumab reversed the epidermal barrier defects and improved the global molecular signature of AD. This review seeks to provide an overview on the development of dupilumab as the first target-specific biological treatment for AD, with a description of the clinical trials that have been performed in different age groups, their outcomes, and reported adverse effects. Novel aspects of dupilumab treatment, as well as the current knowledge on the molecular and cellular mechanisms underlying the treatment of AD with dupilumab, are summarized and discussed.

Identifiants

DOI: 10.1097/DER.0000000000000905 PMID: 35674510

pubmed: 35674510

doi: 10.1097/DER.0000000000000905

pii: 01206501-990000000-00024

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Déclaration de conflit d'intérêts

The author has no conflicts of interest to declare.

Références

Tan HT, Sugita K, Akdis CA. Novel biologicals for the treatment of allergic diseases and asthma. Curr Allergy Asthma Rep 2016;16(10):70.

Boyman O, Kaegi C, Akdis M, et al. EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders. Allergy 2015;70(7):727–754.

Weidinger S, Novak N. Atopic dermatitis. Lancet 2016;387(10023):1109–1122.

Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 2012;130(6):1344–1354.

Moreno AS, McPhee R, Arruda LK, et al. Targeting the T helper 2 inflammatory axis in atopic dermatitis. Int Arch Allergy Immunol 2016;171(2):71–80.

Brandt EB, Sivaprasad U. TH2 cytokines and atopic dermatitis. J Clin Cell Immunol 2011;2(3):110.

Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol 2017;13(5):425–437.

Bieber T, D'Erme AM, Akdis CA, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go? J Allergy Clin Immunol 2017;139(4S):S58–S64.

Gooderham MJ, Hong HC, Eshtiaghi P, et al. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol 2018;78(3 suppl 1):S28–S36.

Shirley M. Dupilumab: first global approval. Drugs 2017;77(10):1115–1121.

U.S. Food and Drug Administration (FDA). Drugs at FDA: FDA-approved drugs. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761055lbl.pdf. Accesed October 20, 2021.

Kovalenko P, DiCioccio AT, Davis JD, et al. Exploratory population PK analysis of dupilumab, a fully human monoclonal antibody against IL-4Rα, in atopic dermatitis patients and normal volunteers. CPT Pharmacometrics Syst Pharmacol 2016;5(11):617–624.

Webb DC, Cai Y, Matthaei KI, et al. Comparative roles of IL-4, IL-13, and IL-4Ralpha in dendritic cell maturation and CD4+ TH2 cell function. J Immunol 2007;178(1):219–227.

Lutz MB, Schnare M, Menges M, et al. Differential functions of IL-4 receptor types I and II for dendritic cell maturation and IL-12 production and their dependency on GM-CSF. J Immunol 2002;169(7):3574–3580.

Tel J, Torensma R, Figdor CG, et al. IL-4 and IL-13 alter plasmacytoid dendritic cell responsiveness to CpG DNA and herpes simplex virus-1. J Invest Dermatol 2011;131(4):900–906.

Akdis M, Burgler S, Crameri R, et al. Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011;127(3):701–721.e1-70.

Gutermuth J, Pink AE, Worm M, et al. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol 2022;186:440–452.

Chiricozzi A, Gori N, Maurelli M, et al. Biological agents targeting interleukin-13 for atopic dermatitis. Expert Opin Biol Ther 2022;1–9.

Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016;375(24):2335–2348.

Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017;389(10086):2287–2303.

Thaçi D, L Simpson E, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci 2019;94(2):266–275.

de Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol 2018;178(5):1083–1101.

Zhao Y, Wu L, Lu Q, et al. The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2022;186:633–641.

Silverberg JI, Yosipovitch G, Simpson EL, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol 2020;82:1328–1336.

Blauvelt A, Rosmarin D, Bieber T, et al. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials. Br J Dermatol 2019;181(1):196–197.

Blauvelt A, de Bruin-Weller M, Simpson EL, et al. dupilumab with topical corticosteroids provides rapid and sustained improvement in adults with moderate-to-severe atopic dermatitis across anatomic regions over 52 weeks. Dermatol Ther (Heidelb) 2022;12:223–231.

Worm M, Simpson EL, Thaçi D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020;156:131–143.

Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol 2019;81(1):143–151.

Ariëns LFM, van der Schaft J, Bakker DS, et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry. Allergy 2020;75(1):116–126.

Abraham S, Haufe E, Harder I, et al. Implementation of dupilumab in routine care of atopic eczema: results from the German National Registry TREATgermany. Br J Dermatol 2020;183:382–384.

de Wijs LEM, Bosma AL, Erler NS, et al. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data. Br J Dermatol 2020;182(2):418–426.

Uchida H, Kamata M, Mizukawa I, et al. Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study. Br J Dermatol 2019;181(5):1083–1085.

Armario-Hita JC, Pereyra-Rodriguez J, Silvestre JF, et al. Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series. Br J Dermatol 2019;181(5):1072–1074.

Jang DH, Heo SJ, Kook HD, et al. A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world. Sci Rep 2021;11(1):23539.

Silverberg JI, Simpson EL, Boguniewicz M, et al. Dupilumab provides rapid and sustained clinically meaningful responses in adults with moderate-to-severe atopic dermatitis. Acta Derm Venereol 2021;101(11):adv00585.

Raffi J, Suresh R, Botto N, et al. The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: a retrospective chart review. J Am Acad Dermatol 2020;82(1):132–138.

Crepy MN, Nosbaum A, Bensefa-Colas L. Blocking type 2 inflammation by dupilumab does not control classic (type 1–driven) allergic contact dermatitis in chronic hand eczema. Contact Dermatitis 2019;81(2):145–147.

Hoot JW, Douglas JD, Falo LD Jr. Patch testing in a patient on dupilumab. Dermatitis 2018;29(3):164.

Stout M, Silverberg JI. Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis. J Am Acad Dermatol 2019;81(1):157–162.

Jo CE, Mufti A, Sachdeva M, et al. Effect of dupilumab on allergic contact dermatitis and patch testing. J Am Acad Dermatol 2021;84(6):1772–1776.

Dhingra N, Shemer A, Correa da Rosa J, et al. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J Allergy Clin Immunol 2014;134(2):362–372.

Licari A, Castagnoli R, Marseglia A, et al. Dupilumab to treat type 2 inflammatory diseases in children and adolescents. Paediatr Drugs 2020;22:295–310.

Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol 2019.

Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol 2020;182(1):85–96.

Paller AS, Bansal A, Simpson EL, et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol 2020;21(1):119–131.

Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol 2020;83(5):1282–1293.

Lio PA. Considerations in weaning or withdrawing dupilumab therapy-nothing is forever. JAMA Dermatol 2020;156:119–120.

Bosma AL, de Wijs LEM, Hof MH, et al. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. J Am Acad Dermatol 2020;83(5):1375–1384.

Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS One 2012;7(4):e33486.

Hsu L, Armstrong AW. Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response. Expert Rev Clin Immunol 2013;9(10):949–958.

Popiela MZ, Barbara R, Turnbull AMJ, et al. Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. Eye (Lond) 2021;35(12):3277–3284.

Barbé J, Poreaux C, Remen T, et al. Prevalence of ocular disease during dupilumab treatment for atopic dermatitis: a bicentric retrospective comparative cohort study. Int J Dermatol 2021;60(12):1520–1528.

Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol 2019;181(3):459–473.

Wollenberg A, Ariens L, Thurau S, et al. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab—clinical characteristics and treatment. J Allergy Clin Immunol Pract 2018;6(5):1778–1780.e1.

Bakker DS, Ariens LFM, van Luijk C, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol 2019;180(5):1248–1249.

Bakker DS, Ter Linde JJM, Amini MM, et al. Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: a case series study. Allergy 2021;76(12):3814–3817.

Ou Z, Chen C, Chen A, et al. Adverse events of dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis. Int Immunopharmacol 2018;54:303–310.

Salgüero-Fernández I, Gonzalez de Domingo MA, Suarez D, et al. Dermatitis and alopecia in a patient treated with dupilumab: a new adverse effect? Clin Exp Dermatol 2019;44(3):e41–e43.

Flanagan K, Sperling L, Lin J. Drug-induced alopecia after dupilumab therapy. JAAD Case Rep 2019;5(1):54–56.

Patruno C, Napolitano M, Ferrillo M, et al. Dupilumab and alopecia: a Janus effect. Dermatol Ther 2019;32(5):e13023.

Uchida H, Kamata M, Watanabe A, et al. Dupilumab improved alopecia areata in a patient with atopic dermatitis: a case report. Acta Derm Venereol 2019;99(7):675–676.

Darrigade AS, Legrand A, Andreu N, et al. Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata. Br J Dermatol 2018;179(2):534–536.

Eichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis. Am J Clin Dermatol 2019;20(3):443–456.

Carugno A, Raponi F, Locatelli AG, et al. No evidence of increased risk for Coronavirus Disease 2019 (COVID-19) in patients treated with dupilumab for atopic dermatitis in a high-epidemic area—Bergamo, Lombardy, Italy. J Eur Acad Dermatol Venereol 2020;34(9):e433–e434.

Napolitano M, Patruno C, Ruggiero A, et al. Safety of dupilumab in atopic patients during COVID-19 outbreak. J Dermatolog Treat 2020;1–2.

Ferrucci S, Romagnuolo M, Angileri L, et al. Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports. J Eur Acad Dermatol Venereol 2020;34(7):e303–e304.

Hansel K, Patruno C, Antonelli E, et al. Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic. Clin Exp Dermatol 2022;47(1):165–167.

Chiricozzi A, Talamonti M, De Simone C, et al. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry. Allergy 2021;76(6):1813–1824.

Kridin K, Schonmann Y, Solomon A, et al. Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment—a population-based cohort study. Immunol Res 2022;70:106–113.

Ungar B, Glickman JW, Golant AK, et al. COVID-19 symptoms are attenuated in moderate-to-severe atopic dermatitis patients treated with dupilumab. J Allergy Clin Immunol Pract 2022;10(1):134–142.

Wu JJ, Martin A, Liu J, et al. The risk of COVID-19 infection in patients with atopic dermatitis: a retrospective cohort study. J Am Acad Dermatol 2022;86(1):243–245.

Thyssen JP, Vestergaard C, Barbarot S, et al. European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. J Eur Acad Dermatol Venereol 2021;35(5):e308–e311.

Pfaar O, Klimek L, Hamelmann E, et al. COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals)—a position paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergology (AeDA). Allergol Select 2021;5:140–147.

Leasure AC, Cowper SE, McNiff J, et al. Generalized eczematous reactions to the Pfizer-BioNTech COVID-19 vaccine. J Eur Acad Dermatol Venereol 2021;35(11):e716–e717.

Corbeddu M, Diociaiuti A, Vinci MR, et al. Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 vaccine: an Italian single-centre case series. J Eur Acad Dermatol Venereol 2021;35(8):e483–e485.

Potestio L, Napolitano M, Bennardo L, et al. Atopic dermatitis exacerbation after Covid-19 vaccination in dupilumab treated patients. J Eur Acad Dermatol Venereol 2022.

Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014;371(2):130–139.

Hamilton JD, Suárez-Fariñas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 2014;134(6):1293–1300.

Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol 2019;143(1):155–172.

Rohner MH, Thormann K, Cazzaniga S, et al. Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis. Allergy 2021;76(4):1268–1270.

Glickman JW, Dubin C, Han J, et al. Comparing cutaneous molecular improvement with different treatments in atopic dermatitis patients. J Allergy Clin Immunol 2020;145(4):1285–1288.

Callewaert C, Nakatsuji T, Knight R, et al. IL-4Rα blockade by dupilumab decreases Staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis. J Invest Dermatol 2020;140(1):191–202.e7.

Olesen CM, Ingham AC, Thomsen SF, et al. Changes in skin and nasal microbiome and staphylococcal species following treatment of atopic dermatitis with dupilumab. Microorganisms 2021;9(7):1487.

Trichot C, Faucheux L, Karpf L, et al. TH cell diversity and response to dupilumab in patients with atopic dermatitis. J Allergy Clin Immunol 2021;147(2):756–759.

He H, Olesen CM, Pavel AB, et al. Tape-strip proteomic profiling of atopic dermatitis on dupilumab identifies minimally invasive biomarkers. Front Immunol 2020;11:1768.

He H, Li R, Choi S, et al. Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis. Ann Allergy Asthma Immunol 2020;124(1):70–78.

Brunner PM, Suárez-Fariñas M, He H, et al. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Sci Rep 2017;7(1):8707.

Yamauchi T, Sasaki S, Lee ES, et al. Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis. Int J Dermatol 2021;60(2):190–195.

Bakker DS, Ariens LFM, Giovannone B, et al. EASI p-EASI: predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers. Allergy 2020;75(12):3287–3289.